Hemophilia A - Epidemiology Forecast - 2034
Description
Key Highlights
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting Factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished using donated whole blood, subsequently plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which have revolutionized the treatment of Hemophilia A.
Approximately 30% of patients with severe hemophilia A develop neutralizing anti-FVIII alloantibodies (inhibitors), rendering FVIII replacement ineffective. The standard of care therapy for patients with inhibitors involves inducing immune tolerance through high-dose, high-frequency FVIII and treatment with bypassing agents.
The total diagnosed prevalent population of Hemophilia A in the 7MM comprised nearly 49,500 cases in 2024 and is projected to increase during the forecast period.
In the 7MM, the highest diagnosed prevalent cases of Hemophilia A were in the United States, accounting for nearly 30% of cases in 2024.
In Japan, the total diagnosed prevalent cases of Hemophilia A with inhibitors are estimated to be approximately 900 in 2024 and are expected to increase over the forecast period.
In 2024, the prevalent cases of mild Hemophilia A in the United States were identified to be ~36%, moderate at ~17%, and severe at ~47%.
In the UK, the diagnosed prevalent cases of Hemophilia A were highest among the age group 19–44 years, and the least were between 0 years and 4 years in 2024.
DelveInsight’s ‘Hemophilia A – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Hemophilia A Disease Understanding
Hemophilia A Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting Factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donating whole blood, subsequently by plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A. Although hemophilia is usually diagnosed at birth, the disorder can also be acquired later in life if the body begins to produce antibodies that attack and destroy clotting factors. However, this acquired type of hemophilia is very rare.
Hemophilia A Diagnosis
The symptoms of Hemophilia A can vary greatly from one person to another; it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and the overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.
Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.
Further details related to diagnosis are provided in the report…
Hemophilia A Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Hemophilia A, age-specific diagnosed prevalent cases of Hemophilia A, severity-specific diagnosed prevalent cases of Hemophilia A, diagnosed prevalent cases of Hemophilia A with or without Inhibitors and treated pool of Hemophilia A in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2020 to 2034.
In the 7MM, ~6,800 cases accounted for inhibitors and ~42,700 cases for noninhibitors in 2024.
In EU4 and the UK, the diagnosed prevalence of Hemophilia A without inhibitors was found to be around 24,900.
Among the EU4 and the UK, Spain accounted for approximately 12% of the total diagnosed prevalent population of Hemophilia A in 2024.
In 2024, the prevalent cases of mild Hemophilia A in Japan were identified to be ~1,550, moderate as ~1,400, and severe as ~3,000.
In the US, ~2,400 cases accounted for inhibitors and ~12,000 cases for noninhibitor in 2024.
Scope of the Report
The report covers a segment of an executive summary and descriptive overview of Hemophilia A, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.
A detailed review of the Hemophilia A epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Report Insights
Patient population
Country-wise epidemiology distribution
Report Key Strengths
10-year forecast
7MM coverage
Hemophilia A epidemiology segmentation
Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
What are the disease risk, burden, and unmet needs of Hemophilia A? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hemophilia A?
What is the historical Hemophilia A patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of Hemophilia A at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalent population of Hemophilia A during the study period (2020–2034)?
At what CAGR is the population expected to grow across the 7MM during the study period (2020–2034)?
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia A market.
To understand the future market competition in the Hemophilia A market and an insightful review of the key market drivers and barriers.
Quantify patient populations in the global Hemophilia A market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A in the US, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The Hemophilia A Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and highlights disease trends over a 10-year forecast period using reputable sources.
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting Factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished using donated whole blood, subsequently plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which have revolutionized the treatment of Hemophilia A.
Approximately 30% of patients with severe hemophilia A develop neutralizing anti-FVIII alloantibodies (inhibitors), rendering FVIII replacement ineffective. The standard of care therapy for patients with inhibitors involves inducing immune tolerance through high-dose, high-frequency FVIII and treatment with bypassing agents.
The total diagnosed prevalent population of Hemophilia A in the 7MM comprised nearly 49,500 cases in 2024 and is projected to increase during the forecast period.
In the 7MM, the highest diagnosed prevalent cases of Hemophilia A were in the United States, accounting for nearly 30% of cases in 2024.
In Japan, the total diagnosed prevalent cases of Hemophilia A with inhibitors are estimated to be approximately 900 in 2024 and are expected to increase over the forecast period.
In 2024, the prevalent cases of mild Hemophilia A in the United States were identified to be ~36%, moderate at ~17%, and severe at ~47%.
In the UK, the diagnosed prevalent cases of Hemophilia A were highest among the age group 19–44 years, and the least were between 0 years and 4 years in 2024.
DelveInsight’s ‘Hemophilia A – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Hemophilia A Disease Understanding
Hemophilia A Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting Factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donating whole blood, subsequently by plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A. Although hemophilia is usually diagnosed at birth, the disorder can also be acquired later in life if the body begins to produce antibodies that attack and destroy clotting factors. However, this acquired type of hemophilia is very rare.
Hemophilia A Diagnosis
The symptoms of Hemophilia A can vary greatly from one person to another; it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and the overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.
Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.
Further details related to diagnosis are provided in the report…
Hemophilia A Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Hemophilia A, age-specific diagnosed prevalent cases of Hemophilia A, severity-specific diagnosed prevalent cases of Hemophilia A, diagnosed prevalent cases of Hemophilia A with or without Inhibitors and treated pool of Hemophilia A in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2020 to 2034.
In the 7MM, ~6,800 cases accounted for inhibitors and ~42,700 cases for noninhibitors in 2024.
In EU4 and the UK, the diagnosed prevalence of Hemophilia A without inhibitors was found to be around 24,900.
Among the EU4 and the UK, Spain accounted for approximately 12% of the total diagnosed prevalent population of Hemophilia A in 2024.
In 2024, the prevalent cases of mild Hemophilia A in Japan were identified to be ~1,550, moderate as ~1,400, and severe as ~3,000.
In the US, ~2,400 cases accounted for inhibitors and ~12,000 cases for noninhibitor in 2024.
Scope of the Report
The report covers a segment of an executive summary and descriptive overview of Hemophilia A, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.
A detailed review of the Hemophilia A epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Report Insights
Patient population
Country-wise epidemiology distribution
Report Key Strengths
10-year forecast
7MM coverage
Hemophilia A epidemiology segmentation
Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
What are the disease risk, burden, and unmet needs of Hemophilia A? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hemophilia A?
What is the historical Hemophilia A patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of Hemophilia A at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalent population of Hemophilia A during the study period (2020–2034)?
At what CAGR is the population expected to grow across the 7MM during the study period (2020–2034)?
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia A market.
To understand the future market competition in the Hemophilia A market and an insightful review of the key market drivers and barriers.
Quantify patient populations in the global Hemophilia A market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A in the US, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The Hemophilia A Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and highlights disease trends over a 10-year forecast period using reputable sources.
Table of Contents
143 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. Key Events
- 5. Epidemiology Forecast Methodology
- 6. Hemophilia A Market Overview at a Glance
- 6.1. Patient Share (%) Distribution of Hemophilia A in 2020
- 6.2. Patient Share (%) Distribution of Hemophilia A in 2034
- 7. Hemophilia A: Disease Background and Overview
- 7.1. Introduction
- 7.2. Sign and Symptoms
- 7.3. Inheritance Pattern
- 7.4. Molecular Pathogenesis
- 7.5. Pathophysiology
- 7.6. Risk Factors
- 7.7. Diagnosis of Hemophilia A
- 7.7.1. Establishing the Diagnosis
- 7.7.2. Molecular Genetic Testing
- 7.7.3. Screening Tests
- 7.7.4. Clotting Factor Tests
- 7.7.5. Inhibitor Testing
- 8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale: 7MM
- 8.3. Total Diagnosed Prevalent Cases of Hemophilia A in the 7MM
- 8.4. United States Epidemiology
- 8.4.1. Total Diagnosed Prevalent Cases of Hemophilia A in the United States
- 8.4.2. Diagnosed Prevalent Cases of Hemophilia A With Inhibitors and Without Inhibitors in the United States
- 8.4.3. Age-Specific Diagnosed Prevalent Cases of Hemophilia A in the United States
- 8.4.4. Severity-specific Diagnosed Prevalent Cases of Hemophilia A in the United States
- 8.4.5. Treated Patient Pool of Hemophilia A in the United States
- 8.5. EU4 and the UK Epidemiology
- 8.5.1. Total Diagnosed Prevalent Cases of Hemophilia A in EU4 and the UK
- 8.5.2. Diagnosed Prevalent Cases of Hemophilia A With or Without Inhibitors in EU4 and the UK
- 8.5.3. Age-Specific Diagnosed Prevalent Cases of Hemophilia A in EU4 and the UK
- 8.5.4. Severity-specific Diagnosed Prevalent Cases of Hemophilia A in EU4 and the UK
- 8.5.5. Treated Patient Pool of Hemophilia A in EU4 and the UK
- 8.6. Japan Epidemiology
- 8.6.1. Total Diagnosed Prevalent of Hemophilia A in Japan
- 8.6.2. Diagnosed Prevalent Cases of Hemophilia A With Inhibitors and Without Inhibitors in Japan
- 8.6.3. Age-Specific Diagnosed Prevalent Cases of Hemophilia A in Japan
- 8.6.4. Severity-specific Diagnosed Prevalent Cases of Hemophilia A in Japan
- 8.6.5. Treated Patient Pool of Hemophilia A in Japan
- 9. Appendix
- 9.1. Bibliography
- 9.2. Report Methodology
- 10. DelveInsight Capabilities
- 11. Disclaimer
- 12. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
